// App-Quantinova.ai

P1135 : SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE

Researchers

Presenter

  • David Belada

Principal Investigators

  • Sirpa Lepp

  • Bj�rn E. Wahlin

  • Marcel Nijland

  • Jacob Haaber Christensen

  • Sven de Vos

  • Harald Holte

  • Liwei Wang

  • Minh Dinh

  • Brian Elliott

  • Lorenzo Falchi

Medical Centers

  • AbbVie Inc ,North Chicago, IL,États-unis

  • Oslo University Hospital and KG Jebsen Center for B-cell Malignancies,Oslo,Norway

  • Genmab,Princeton,États-unis

  • Genmab,Princeton,Estados Unidos

  • The Christie NHS Foundation Trust and Manchester Cancer Research Centre,Manchester,Regno Unito

  • Lymphoma Service,Memorial Sloan Kettering Cancer Center,New York,Stati Uniti

  • The Christie NHS Foundation Trust and Manchester Cancer Research Centre,Manchester,Regno Unito

  • AbbVie Inc ,North Chicago, IL,Vereinigte Staaten

  • Karolinska Institutet, Stockholm, Sweden

  • Fourth Department of Internal Medicine - Hematology, Charles University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic

  • AbbVie Inc ,North Chicago, IL,Stati Uniti

  • Genmab,Princeton,Vereinigte Staaten

  • Oslo University Hospital and KG Jebsen Center for B-cell Malignancies,Oslo,Norway

  • Odense University hospital, Odense

  • Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki, Helsinki, Finland

  • University Medical Center Groningen; University of Groningen

  • Karolinska Institutet,Stockholm,Швеция

  • Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki, Helsinki, Finland

  • AbbVie, N Chicago, United States

  • Odense University Hospital, Odense, Denmark

  • Oslo University Hospital and KG Jebsen Center for B-cell Malignancies,Oslo,Norway

  • Endocrinology Service, Memorial Sloan Kettering Cancer Center, New York, United States

  • Genmab,Princeton,USA

  • The Christie NHS Foundation Trust and Manchester Cancer Research Centre,Manchester,Regno Unito

  • Ronald Reagan University of Cali

  • Oslo University Hospital and KG Jebsen Center for B-cell Malignancies,Oslo,Norway

  • Genmab,Princeton,Stati Uniti

  • Genmab,Princeton, NJ,United States

  • Lymphoma Service,Memorial Sloan Kettering Cancer Center,New York,Stati Uniti

  • University Medical Center, University of Groningen, Groningen, Netherlands

  • Ronald Reagan University of California Los Angeles Medical Center,Santa Monica, CA,United States

  • Karolinska Institutet, Stockholm, Sweden

  • Odense University Hospital, Odense, Denmark

  • Oslo University Hospital and KG Jebsen Center for B-cell Malignancies,Oslo,Norway

  • Lymp

  • Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki, Helsinki, Finland

  • Odense University Hospital, Odense, Denmark

  • Odense University Hospital, Odense, Denmark

  • University of California Los Angeles Medical Center, Los Angeles, CA, USA

  • Karolinska Institutet, Stockholm, Sweden

  • Lymphoma Service,Memorial Sloan Kettering Cancer Center,New York,Stati Uniti

  • Genmab,Princeton,Vereinigte Staaten

  • Memorial Sloan Kettering Cancer Center,New York ,États-unis

  • University Medical Center Groningen and University of Groningen,Groningen,Paesi Bassi

  • 2nd Department of Intern

  • University Medical Center, University of Groningen, Groningen, Netherlands

  • The Ch

  • Odense University Hospital, Odense, Denmark

  • University Medical Center, University of Groningen, Groningen, Netherlands

  • Karolinska Institutet, Stockholm, Sweden

  • The Christie NHS Foundation Trust and Manchester Cancer Research Centre,Manchester,Regno Unito

  • AbbVie Inc ,North Chicago, IL,Vereinigte Staaten

  • AbbVie Inc ,North Chicago, IL,Estados Unidos

  • Karolinska Institutet, Stockholm, Sweden

  • 4th Department of Internal Medicine - Hematology,University Hospital Hradec Kralove,Hradec Kralove,Rep. Ceca

  • Helsinki University Hospital Comprehensive Cancer Centre and University of Helsinki, Helsinki, Finland

  • Karolinska Institutet, Stockholm, Sweden

  • Odense University Hospital, Odense, Denmark

  • University of California Los Angeles Medical Center, Los Angeles, CA, USA

  • Karolinska Institutet, Stockholm, Sweden

  • Karolinska Institutet,Stockholm,Suécia

  • University of California Los Angeles Medical Center, Los Angeles, CA, USA

  • 4th Department of Internal Medicine - Hematology,University Hospital Hradec Kralove,Hradec Kralove,Rep. Ceca

  • AbbVie, N Chicago, USA

Locations

  • Czech Republic

  • Finland

  • Sweden

  • Netherlands

  • Denmark

  • United States

  • Colombia

  • Norway

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

Biomarkers

  • Cytokeratin 20

  • Twist-related protein 1

Drug/Treatment

  • Lenalidomide

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT04663347

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved